Literature DB >> 11998794

Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.

John A Heath1, Emmett H Broxson, Mukund G Dole, Daniel A Filippa, Diane George, David Lyden, Ira J Dunkel.   

Abstract

Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a serious disorder seen in various states of immunodeficiency, often with a fatal outcome. In this article, a patient with EBV-lymphoma after autologous stem cell rescue for treatment of a nonhematologic solid tumor is described. The child, a 4-year-old boy, had unilateral retinoblastoma with metastatic spread to the central nervous system. He had previously received both local tumor bed and craniospinal radiation therapy together with intensive myeloablative alkylator chemotherapy before autologous stem cell rescue. Histologically confirmed lymphoma with evidence of active EBV proliferation developed within cervical lymph nodes 3 weeks after his first autologous stem cell rescue. A complete clinical remission of the lymphadenopathy was obtained after infusions of rituximab (an anti-CD20 monoclonal antibody), acyclovir, and high-titer anticytomegalovirus immunoglobulin. The patient died approximately 6 months later of persistent and progressive retinoblastoma without any clinical evidence of lymphoma. It is concluded that EBV-LPD should be included in the differential diagnosis in patients in whom lymphadenopathy develops after autologous stem cell rescue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11998794     DOI: 10.1097/00043426-200202000-00022

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Use of rituximab in three children with relapsed/refractory Burkitt lymphoma.

Authors:  Sinan Akbayram; Murat Doğan; Cihangir Akgün; Fatih Erbey; Hüseyin Caksen; Ahmet Faik Oner
Journal:  Target Oncol       Date:  2010-09-22       Impact factor: 4.493

2.  Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma.

Authors:  Sakura Izumiya; Mitsuaki Ishida; Keiko Hodohara; Takashi Yoshida; Hidetoshi Okabe
Journal:  Oncol Lett       Date:  2012-04-03       Impact factor: 2.967

3.  Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Authors:  Richard A Nash; Roger Dansey; Jan Storek; George E Georges; James D Bowen; Leona A Holmberg; George H Kraft; Maureen D Mayes; Kevin T McDonagh; Chien-Shing Chen; John Dipersio; C Fred Lemaistre; Steven Pavletic; Keith M Sullivan; Julie Sunderhaus; Daniel E Furst; Peter A McSweeney
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

4.  An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma.

Authors:  J L Powell; N J Bunin; C Callahan; R Aplenc; G Griffin; S A Grupp
Journal:  Bone Marrow Transplant       Date:  2004-03       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.